These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27538952)

  • 1. Effect of Xinyue capsules on patients with coronary heart disease after percutaneous coronary intervention: study protocol for a randomized controlled trial.
    Guo M; Zi MJ; Xi RX; Yang QN; Bai RN; Zhang YS; Wang YH; Wang PL; Shi DZ
    Trials; 2016 Aug; 17():412. PubMed ID: 27538952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial.
    Guo M; Wang P; Du J; Fu C; Yang Q; Gao Z; Zhu M; Lv S; Deng Y; Li T; Shi D; Working Group FTX
    Pharmacol Res; 2020 Aug; 158():104883. PubMed ID: 32446979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial.
    Wang Y; Wang X; Wang J; Li B; Yu R; Hu Y; Li X; Peng G; Zhang M; Zhu M
    Trials; 2020 Mar; 21(1):287. PubMed ID: 32197640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention.
    Mao C; Fu XH; Yuan JQ; Yang ZY; Chung VC; Qin Y; Huang Y; Tam WW; Kwong JS; Xie W; Tang JL
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD010237. PubMed ID: 25994229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention.
    Zhang DW; Wang SL; Wang PL; Du JP; Gao ZY; Wang CL; Xu H; Shi DZ
    J Ethnopharmacol; 2020 Feb; 248():112354. PubMed ID: 31689480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled clinical study on Yiqi Liangxue Shengji prescription for intervention cardiac function of acute myocardial infarction with ischemia-reperfusion injury.
    Chen C; Xia J; Feng R; Wan J; Zhou K; Lin Q; Li D
    Medicine (Baltimore); 2021 Mar; 100(10):e24944. PubMed ID: 33725857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized, double-blind, placebo-controlled trial.
    Li X; Lai XL; Fei YT; Shang JJ; Zhou Q; Sun XY; Xing WL; Jia SH; Liu HX
    Ann Transl Med; 2019 Mar; 7(6):119. PubMed ID: 31032274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention.
    Li X; Zhang Y; Liu HX; Shang JJ; Zhou Q; Li AY; Lai XL; Xing WL; Jia SH
    Complement Ther Med; 2022 Oct; 69():102841. PubMed ID: 35643381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease.
    Zheng GH; Liu JP; Chu JF; Mei L; Chen HY
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD009581. PubMed ID: 23728695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A randomized double-blinded controlled trial of Xuefu Zhuyu Capsule on short-term quality of life in unstable anginal patients with blood-stasis syndrome after percutaneous coronary intervention].
    Chu FY; Wang J; Sun XW; Xing YW; Yao KW; Wang SH; Li ZZ
    Zhong Xi Yi Jie He Xue Bao; 2009 Aug; 7(8):729-35. PubMed ID: 19671410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients.
    Shang QH; Xu H; Lu XY; Wen C; Shi DZ; Chen KJ
    Chin J Integr Med; 2011 Sep; 17(9):669-74. PubMed ID: 21910067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on Suxiao Jiuxin Pills in the Treatment of Patients with Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention: A Multicenter Randomized Double-Blind Placebo-Controlled Trial.
    Shen Z; Chen T; Deng B; Fan M; Hua J; Zhang M; Wang X
    J Altern Complement Med; 2020 Nov; 26(11):1055-1063. PubMed ID: 32716206
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.
    Tian PP; Li J; Gao J; Li Y
    BMJ Open; 2018 Feb; 8(2):e018052. PubMed ID: 29444778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
    Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H
    Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial.
    Li S; Guo M; Mao H; Gao Z; Xu H; Shi D
    Trials; 2016 Sep; 17(1):451. PubMed ID: 27628038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial.
    Zhou T; Gong Y; Li J; Wang Y; Wang X
    Trials; 2023 Mar; 24(1):209. PubMed ID: 36945020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study.
    Wang CL; Huan N; Wang PL; Geng QS; Ma WL; Ma LH; Jiang HY; Meng XP; Zhang DW; Gou XJ; Hu DY; Chen KJ
    Chin J Integr Med; 2023 Mar; 29(3):195-204. PubMed ID: 36301456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis: study protocol of a multicenter randomized controlled trial.
    Liu J; Huang CB; Wang Y; Xu GQ; Cheng YY; Feng YX; Liu L; Qi YJ
    J Integr Med; 2013 Nov; 11(6):428-34. PubMed ID: 24299607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.